Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, TARSUS PHARMACEUTICALS, INC. reported revenue of $451M, up 146.7% year over year. Operating margin was -15.7% and net margin -14.7%, on a free-cash-flow margin of -4.9% with capital expenditure at 2.2% of revenue. Every figure is computed directly from TARS's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $451M | -15.7% | -14.7% |
| FY2024 | $183M | -65.9% | -63.2% |
| FY2023 | $17M | -820.5% | -778.9% |
| FY2022 | $26M | -242.9% | -240.5% |
| FY2021 | $57M | -21.3% | -24.2% |
How does TARS compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.